199 related articles for article (PubMed ID: 1705230)
1. Pharmacological activity of cholecystokinin analogues modified in the Met28-Gly29 region.
Mendre C; Rodriguez M; Lignon MF; Galas MC; Gueudet C; Worms P; Martinez J
Eur J Pharmacol; 1990 Sep; 186(2-3):213-22. PubMed ID: 1705230
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.
Rodriguez M; Galas MC; Lignon MF; Mendre C; Laur J; Aumelas A; Martinez J
J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity.
Galas MC; Lignon MF; Rodriguez M; Mendre C; Fulcrand P; Laur J; Martinez J
Am J Physiol; 1988 Feb; 254(2 Pt 1):G176-82. PubMed ID: 2450468
[TBL] [Abstract][Full Text] [Related]
4. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors.
Rodriguez M; Lignon MF; Galas MC; Amblard M; Martinez J
Mol Pharmacol; 1990 Sep; 38(3):333-41. PubMed ID: 1698251
[TBL] [Abstract][Full Text] [Related]
5. Analogs of Ac-CCK-7 incorporating dipeptide mimics in place of Met28-Gly29.
Tilley JW; Danho W; Shiuey SJ; Kulesha I; Swistok J; Makofske R; Michalewsky J; Triscari J; Nelson D; Weatherford S
J Med Chem; 1992 Oct; 35(21):3774-83. PubMed ID: 1433191
[TBL] [Abstract][Full Text] [Related]
6. A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.
Mendre C; Rodriquez M; Gueudet C; Lignon MF; Galas MC; Laur J; Worms P; Martinez J
J Biol Chem; 1988 Aug; 263(22):10641-5. PubMed ID: 3392031
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of some cholecystokinin analogues substituted in position 29 by a beta-alanine.
Rodriguez M; Rolland M; Lignon MF; Galas MC; Laur J; Aumelas A; Martinez J
Int J Pept Protein Res; 1989 Nov; 34(5):394-404. PubMed ID: 2482263
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways.
Yoshida H; Tsunoda Y; Owyang C
Am J Physiol; 1997 Sep; 273(3 Pt 1):G735-47. PubMed ID: 9316479
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
[TBL] [Abstract][Full Text] [Related]
11. Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists.
Shiosaki K; Lin CW; Kopecka H; Craig R; Wagenaar FL; Bianchi B; Miller T; Witte D; Nadzan AM
J Med Chem; 1990 Nov; 33(11):2950-2. PubMed ID: 1700123
[No Abstract] [Full Text] [Related]
12. A synthetic peptide derivative that is a cholecystokinin receptor antagonist.
Lignon MF; Galas MC; Rodriguez M; Laur J; Aumelas A; Martinez J
J Biol Chem; 1987 May; 262(15):7226-31. PubMed ID: 2438274
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors.
Rodriguez M; Amblard M; Galas MC; Lignon MF; Aumelas A; Martinez J
Int J Pept Protein Res; 1990 May; 35(5):441-51. PubMed ID: 2376470
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of new cholecystokinin analogues.
Maletínská L; Lignon MF; Galas MC; Bernad N; Pírková J; Hlavácek J; Slaninová J; Martinez J
Eur J Pharmacol; 1992 Nov; 222(2-3):233-40. PubMed ID: 1280592
[TBL] [Abstract][Full Text] [Related]
15. Structural requirements of CCK analogues to differentiate second messengers and pancreatic secretion.
Tsunoda Y; Yoshida H; Owyang C
Am J Physiol; 1996 Jul; 271(1 Pt 1):G8-19. PubMed ID: 8760101
[TBL] [Abstract][Full Text] [Related]
16. N alpha-carboxyacyl analogues of CCK with a substituted Gly: interaction with pancreatic and gallbladder CCK receptors.
von Schrenck T; Müller K; Schulze C; Mirau S; Raedler A; Greten H
Peptides; 1993; 14(6):1309-15. PubMed ID: 7510882
[TBL] [Abstract][Full Text] [Related]
17. The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
Sarri E; Ramos B; Salido GM; Claro E
Br J Pharmacol; 2001 Aug; 133(8):1227-34. PubMed ID: 11498507
[TBL] [Abstract][Full Text] [Related]
18. N-terminal fragments of CCK-(26-33) as cholecystokinin receptor antagonists in guinea pig pancreatic acini.
Gardner JD; Knight M; Sutliff VE; Jensen RT
Am J Physiol; 1985 Jan; 248(1 Pt 1):G98-102. PubMed ID: 2578257
[TBL] [Abstract][Full Text] [Related]
19. Cyclic cholecystokinin analogues with high selectivity for central receptors.
Charpentier B; Pelaprat D; Durieux C; Dor A; Reibaud M; Blanchard JC; Roques BP
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1968-72. PubMed ID: 3162318
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of 2-phenylethyl ester analogues of C-terminal heptapeptide of cholecystokinin modified in Trp 30 region.
Rolland M; Rodriguez M; Lignon MF; Galas MC; Laur J; Aumelas A; Martinez J
Int J Pept Protein Res; 1991 Aug; 38(2):181-92. PubMed ID: 1723720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
